Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors

Gene Therapy

Volumn 22, Issue 7, 2015, Pages 528-535

  Sun, Y ^a,b   Peng, S ^b   Qiu, J ^b,c   Miao, J ^b,d   Yang, B ^b   Jeang, J ^b   Hung, C F ^b,e   Wu, T C ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; DNA VACCINE; GAMMA INTERFERON; WART VIRUS VACCINE; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; ELECTROPORATION; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; ANIMAL; C57BL MOUSE; CYTOLOGY; IMMUNOLOGY; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; PROCEDURES; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; MUS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; ELECTROPORATION; FEMALE; MICE, INBRED C57BL; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 84934439485     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.17     Document Type: Article

References (21)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Tran NP, Hung CF, Roden R, Wu TC. Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res 2014; 193: 149-171.
4. Lin K, Doolan K, Hung CF, Wu TC. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010; 109: 4-24.
5. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunol Res 2010; 47: 86-112.
6. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009; 19: 97-113.
7. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
8. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669-678.
9. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Therapy 2004; 11: 1011-1018.
10. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009; 27: 5450-5459.
11. Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L et al. Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5: 172ra20.
12. Trimble CL, Clark RA, Thoburn C, Hanson NC, Tassello J, Frosina D et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 2010; 185: 7107-7114.
13. Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNgamma. Clin Cancer Res 2014; 20: 5456-5467.
14. Cuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM et al. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest 2012; 122: 4606-4620.
15. Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 2009; 9: 836-850.
16. Center SKCC. A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3). In: ClinicalTrials. gov [Internet]. National Library of Medicine (US): Bethesda (MD), 2009.
17. Peng S, Song L, Knoff J, Wang JW, Chang YN, Hannaman D et al. Control of HPVassociated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci 2014; 4: 11.
18. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
19. Wu CY, Yang LH, Yang HY, Knoff J, Peng S, Lin YH et al. Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 2014; 20: 644-657.
20. Zeng Q, Peng S, Monie A, Yang M, Pang X, Hung CF et al. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther 2011; 22: 809-819.
21. Decrausaz L, Goncalves AR, Domingos-Pereira S, Pythoud C, Stehle JC, Schiller J et al. A novel mucosal orthotopic murine model of human papillomavirusassociated genital cancers. International journal of cancer. Int J Cancer 2011; 128: 2105-2113.